Braveheart Bio, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
BRVE$19.62+0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive Loss
Condensed Statements of Operations and Comprehensive Loss (unaudited)
(in thousands, except share and per share amounts)
| Three Months Ended | Nine Months Ended | |||
|---|---|---|---|---|
| September 30,2026 | September 30,2025 | September 30,2026 | September 30,2025 | |
| Operating expenses | ||||
| Research and development (includes related party amounts of $1,024 and $7,413 for the three and nine months ended September 30, 2026, respectively, and $0 for the three and nine months ended September 30, 2025) | $17,542 | $9 | $39,581 | $9 |
| In-process research and development (includes related party amounts of $0 for the three and nine months ended September 30, 2026 and $58,409 for the three and nine months ended September 30, 2025) | — | 58,770 | — | 59,218 |
| General and administrative (includes related party amounts of $84 and $159 for the three and nine months ended September 30, 2026, respectively, and nominal amounts for the three and nine months ended September 30, 2025) | 12,607 | 508 | 21,499 | 540 |
| Total operating expenses | 30,149 | 59,287 | 61,080 | 59,767 |
| Loss from operations | (30,149) | (59,287) | (61,080) | (59,767) |
| Other income | ||||
| Interest income | 3,712 | 169 | 5,372 | 169 |
| Other income (expense), net | (58) | — | (55) | — |
| Total other income | $3,654 | $169 | $5,317 | $169 |
| Net loss | $(26,495) | $(59,118) | $(55,763) | $(59,598) |
| Deemed dividends upon issuance of redeemable convertible preferred stock | — | — | (3,615) | — |
| Net loss attributable to common stockholders | $(26,495) | $(59,118) | $(59,378) | $(59,598) |
| Net loss per share, basic and diluted | $(0.51) | $(10.05) | $(2.66) | $(20.46) |
| Weighted-average shares of common stock outstanding, basic and diluted | 52,095,078 | 5,881,011 | 22,285,633 | 2,912,682 |
| Comprehensive loss: | ||||
| Net Loss | $(26,495) | $(59,118) | $(55,763) | $(59,598) |
| Other comprehensive loss: | ||||
| Unrealized loss on investments | (718) | — | (718) | — |
| Comprehensive loss | $(27,213) | $(59,118) | $(56,481) | $(59,598) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.